sulfisoxazole (gantrisin) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Sulfisoxazole is a sulfonamide antibacterial antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfisoxazole acetyl in combination with erythromycin ethylsuccinate is used for treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae. Sulfisoxazole acetyl is a prodrug of sulfisoxazole. Acetyl group is added to make the drug poorly water soluble, and is hydrolyzed in vivo to the active drug. Sulfisoxazole and its acetylated metabolites are excreted primarily by the kidneys through glomerular filtration. Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( phenazopyridine (gantanol), sulfisoxazole (gantrisin) )
|
( sulfisoxazole (gantrisin), erythromycin (ilosone) - other name: eryzole )

Alternative names

3,4-dimethyl-5-sulfanilamidoisoxazole | 3,4-dimethyl-5-sulfonamidoisoxazole | 3,4-dimethyl-5-sulphanilamidoisoxazole | 3,4-dimethyl-5-sulphonamidoisoxazole | 3,4-dimethylisoxazole-5-sulfanilamide | 3,4-dimethylisoxazole-5-sulphanilamide | 4-amino-n-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide | 4-amino-n-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide | 5-(4-aminophenylsulfonamido)-3,4-dimethylisoxazole | 5-(p-aminobenzenesulfonamido)-3,4-dimethylisoxazole | 5-(p-aminobenzenesulphonamido)-3,4-dimethylisoxazole | 5-sulfanilamido-3,4-dimethylisoxazole | 5-sulphanilamido-3,4-dimethyl-isoxazole | acetylsulfisoxazole | alphazole | entusil | erythromycin, 2-amino-5-((aminoacetyl)methylamino)-2,3,5-trideoxy-1-o-(2,6-diamino-2,3,4,6,7-pentadeoxy-beta-l-lyxo-heptopyranosyl)-, (1alpha,2beta,2aalpha,3aalpha)- | eryzole | gantrisin | gantrisin pediatric | lipo gantrisin | mk 0641 | mk-0641 | n(1)-(3,4-dimethyl-5-isoxazolyl)sulfanilamide | n(1)-(3,4-dimethyl-5-isoxazolyl)sulphanilamide | n'-(3,4)dimethylisoxazol-5-yl-sulphanilamide | neazolin | nu-445 | pediazole | sosol | soxazole | soxomide | sulfadimethylisoxazole | sulfafurazol | sulfafurazole | sulfafurazole diolamine | sulfafurazolum | sulfaisoxazole | sulfalar | sulfasoxazole | sulfazin | sulfisonazole | sulfisoxasole | sulfisoxazol | sulfisoxazole | sulfisoxazole acetyl | sulfisoxazole dialamine | sulfisoxazole diolamine | sulfofurazole | sulphadimethylisoxazole | sulphafurazol | sulphafurazole | sulphaisoxazole | sulphisoxazol | sulphofurazole | sulsoxin

Organizations (24)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Otitis Media (approved 1988)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Pneumonia, Pneumocystis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue